Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 5/20 | 0.57 |
| ▸ | CPA1 | P15085 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892795 | 1.00 | ACE (0.60) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL3510333 | 1.00 | ACE (0.60) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL995229 | 0.87 | ALDH1A1 (0.64) | ACENAALAD2MMECPA1ACE2 | |
| SCHEMBL995228 | 0.87 | ALDH1A1 (0.64) | ACENAALAD2MMECPA1ACE2 | |
| SCHEMBL6293500 | 0.87 | ALDH1A1 (0.64) | ACENAALAD2MMECPA1ACE2 | |
| SCHEMBL1991726 | 0.85 | ACE (0.62) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL7769148 | 0.85 | ACE (0.62) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL1991725 | 0.85 | ACE (0.62) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL7769146 | 0.85 | ACE (0.62) | ACEFOLH1NAALAD2MMECPA1 | |
| SCHEMBL4161392 | 0.85 | ACE (0.62) | ACEFOLH1NAALAD2MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552373-B | Industrial preparation method of glycyl-L-tyrosine | 河北一品制药股份有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-112552373-A | Industrial preparation method of glycyl-L-tyrosine | 河北一品制药股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| CN-102718833-A | Preparation method of glycyl-tyrosine | JIANGSU SINCERITY PHARMACEUTICAL CO LTD | 2012-10-10 | — | — | CN | claimed |
| US-5340734-A | In vitro biosynthesis the melanins in presence of a substrate consisting of tyrosine binding single amino acid, a dipeptide or an oligopeptide | BIOSOURCE GENETICS CORPORATION (US) | 1994-08-23 | — | — | US | claimed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4722228-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | The University of Tokyo (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4707390-A1 | LINKER | PeptiDream Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320471-A1 | Method for Producing Compounds, Method for Producing Compound Library, Compound Library, and Screening Method | UNIV TOKYO (JP) | 2025-10-16 | — | — | US | disclosed |
| EP-0742495-A1 | Chelating reagent containing photoresist stripper composition | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5561105-A | MIXTURE OF SOLVENT, AMINE AND CHELATE COMPOUND | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-10-01 | — | — | US | disclosed |
| US-5507978-A | CORROSION RESISTANCE | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5472830-A | Mixture of polar organic solvent, amine and hydroxy amino acid | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0678788-A2 | Non-corrosive photoresist stripping composition | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| US-5424294-A | Treating central and peripheral nervous system disorders | FIDIA S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| US-5264424-A | Modified gangliosides and the functional derivatives thereof | FIDIA S.P.A. (IT) | 1993-11-23 | — | — | US | disclosed |
| EP-0433112-A1 | Modified gangliosides and the functional derivatives thereof | FIDIA S.p.A. (IT) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | ACE 3534/4885FOLH1 2236/4885NAALAD2 2895/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | ACE 2287/4885FOLH1 418/4885NAALAD2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.